Research
Hormonal
New pharmacologic advances in glucagon-like peptide-1 agonists, such as semaglutide, have shown promising effectiveness for weight management.
Plastic surgeons should consider the role of GLP-1 agonists in managing obesity in surgical patients.
StrongSupportsmedium confidence
New pharmacologic advances in glucagon-like peptide-1 agonists, such as semaglutide, have demonstrated promising effectiveness.
Why this rating
The claim is based on emerging clinical evidence for these medications.
Source
Medical Weight Management Considerations in Plastic Surgery
Alisha B. Paranzino et al. · Plastic & Reconstructive Surgery · 2024
DOI 10.1097/prs.0000000000011445
reviewCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →